Acromegaly: Molecular expression of somatostatin receptor subtypes and treatment outcome

Frontiers of Hormone Research

Volumn 35, Issue , 2006, Pages 129-134

  Bronstein, Marcello D ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CYCLOPEPTIDE; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; GROWTH HORMONE; ISOPROTEIN; OCTREOTIDE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

ACROMEGALY; CONFERENCE PAPER; DRUG ANTAGONISM; DRUG COMBINATION; DRUG DESIGN; DRUG RESISTANCE; GENE EXPRESSION; HUMAN; HYPOPHYSIS TUMOR; METABOLISM; TREATMENT OUTCOME;

ACROMEGALY; DOPAMINE AGONISTS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; GENE EXPRESSION; GROWTH HORMONE; HUMANS; OCTREOTIDE; PEPTIDES, CYCLIC; PITUITARY NEOPLASMS; PROTEIN ISOFORMS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 33745794539     PISSN: 03013073     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000094315     Document Type: Conference Paper

References (19)

1. Patel YC, Greenwood MT, Panetta R, Demehyshyn L, Niznik H, Srikant CB: Mini review: the somatostatin receptor family. Life Sci 1995;57:1249-1265.
2. Shimon I: Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs. Endocrine 2003;20:265-269.
3. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D: Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005;90:4465-4473.
4. Jallad RS, Musolino NR, Salgado LR, Bronstein MD: Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf) 2005;63:168-175.
5. Bronstein M, Musolino N, Jallad R, Cendros JM, Ramis J, Obach R, Leselbaum A, Catus F: Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol (Oxf) 2005;63:514-519.
6. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S: Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas: novel potential therapy for functional pituitary tumors. J Clin Invest 1997;100:2386-2392.
7. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC: Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 2000;275:7862-7869.
8. Ben-Shlomo A, Wawrowsky KA, Proekt I, Wolkenfeld NM, Ren SG, Taylor J, Culler MD, Melmed S: Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. J Biol Chem 2005;280:24011-24021.
9. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P: Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001;86:140-145.
10. Weckbecker G, Briner U, Lewis I, Bruns C: SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 2002;143:4123-4130.
11. Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, van der Lely AJ, Beckers A, Lamberts SW: The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 2004;89:1577-1585.
12. van der Hoek J, de Herder WW, Feelders RA, van der Lely AJ, Uitterlinden P, Boerlin V, Bruns C, Poon KW, Lewis I, Weckbecker G, Krahnke T, Hofland LJ, Lamberts SW: A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004;89:638-645.
13. Cozzi R, Attanasio R, Lodrini S, Lasio G: Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 2004;61:209-215.
14. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC: Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000;288:154-157.
15. Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A, Jaquet P: Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 2002;87:5545-5552.
16. Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A: A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005;90:4405-4410.
17. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G: Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001;86:2779-2786.
18. Sharma K, Patel YC, Srikant CB: Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 1996;10:1688-1696.
19. Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A: Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab 2001;86:2976-2981.